Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.
Treatment with axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) — a CD19-directed chimeric antigen receptor T-cell therapy — improved survival outcomes at an incremental price difference well below the typical threshold third-party payers often use to determine insurance coverage, findings presented at Tandem Meetings | Transplantation &